Cogent Biosciences financials
$31.66−0.63%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $7.9M |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $7.9M |
| Gross margin | — | — | — | — | — | 100.0% |
| Operating income | -$333.4M | -$275.9M | -$208.1M | -$147.8M | -$75.6M | -$82.2M |
| Net income | -$277.9M | -$201.4M | -$154.9M | -$101.5M | -$72.3M | -$179.2M |
| Net margin | — | — | — | — | — | −2276.8% |
| Diluted EPS | $-2.16 | $-1.94 | $-1.94 | $-1.73 | $-1.87 | $-16.17 |
| EBITDA | -$330.8M | -$273.5M | -$205.9M | -$147.0M | -$73.6M | -$81.5M |
| Operating cash flow | -$264.4M | -$207.8M | -$153.6M | -$118.6M | -$58.8M | -$35.9M |
| Free cash flow | -$266.0M | -$208.4M | -$156.4M | -$125.5M | -$60.5M | — |
| Diluted shares | 128.9M | 103.9M | 79.7M | 58.7M | 38.7M | 11.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $312.0M | $98.2M | $53.2M | $139.9M | $219.7M | $242.2M |
| Short-term investments | $588.8M | $188.9M | $212.5M | $119.4M | $0.00 | — |
| Total debt | $222.9M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $937.6M | $327.9M | $313.4M | $300.8M | $232.1M | $250.9M |
| Total liabilities | $301.2M | $71.6M | $55.6M | $45.1M | $17.9M | $16.2M |
| Shareholders' equity | $636.4M | $256.3M | $257.8M | $255.7M | $214.2M | $234.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology